Table 2. Grade 3 and 4 adverse events occurring in more that 2% of patients on this phase II study of erlotinib.

Grade 3/4 toxicities	n (%) patients	n (%) cycles
Gr. 4 Constipation	2 (5)	2 (2)
Gr. 4 Abdominal pain/cramping	1 (3)	1 (1)
Gr. 4 Bone pain (left hip/right ankle)	1 (3)	1 (1)
Gr. 3 Diarrhoea	4 (11)	4 (4)
Gr. 3 Rash/desquamation	4 (11)	4 (4)
Gr. 3 Vomiting	3 (8)	3 (3)
Gr. 3 Pain	2 (5)	3 (3)
Gr. 3 Haematuria	2 (5)	4 (4)
Gr. 3 Hyperglycaemia	2 (5)	3 (3)
Gr. 3 Alkaline phosphatase	2 (5)	2 (2)
Gr. 3 Nausea	2 (5)	2 (2)
Gr. 3 Prothrombin time	2 (5)	2 (2)